NYSEHealth CareHealth Care ServicesS&P SmallCap 600
$31.29
-0.55 (-1.73%)
Close of Nov 06, 2026 · end-of-day data
MD 8-K filings in 2025
Every material Form 8-K Pediatrix Medical filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Pediatrix Medical Group reported third-quarter 2025 net income of $71.7 million, or $0.84 per diluted share, up from $19.4 million, or $0.23, a year earlier. Net revenue fell to $492.9 million from $511.2 million, which the company attributed mainly to practice dispositions. The company raised its full-year 2025 Adjusted EBITDA outlook to a range of $270 million to $290 million.
Q3 2025 net revenue $492.9 million vs. $511.2 million a year earlier; same-unit net revenue grew 8.0 percent
Q3 2025 Adjusted EBITDA $87.3 million vs. $60.2 million; Adjusted EPS $0.67 vs. $0.44
Full-year 2025 Adjusted EBITDA now expected at $270 million to $290 million
Cash and cash equivalents $340.1 million at September 30, 2025; total debt $602 million
Pediatrix Medical Group reported second-quarter 2025 net income of $39.3 million, or $0.46 per diluted share, compared with a net loss of $153.0 million a year earlier, which included impairment charges. Net revenue fell to $468.8 million from $504.3 million, mainly due to practice dispositions, and the company raised its full-year 2025 Adjusted EBITDA outlook to a range of $245 million to $255 million from $220 million to $240 million.
Q2 2025 net revenue was $468.8 million, down from $504.3 million in Q2 2024, mainly due to practice dispositions.
Q2 2025 net income was $39.3 million, or $0.46 per diluted share, versus a net loss of $153.0 million in Q2 2024.
Q2 2025 Adjusted EPS was $0.53, compared with $0.34 a year earlier.
Full-year 2025 Adjusted EBITDA outlook raised to $245 million to $255 million from $220 million to $240 million.
Pediatrix Medical Group's board appointed Dr. Kurt Newman as an independent director, effective July 1, 2025. He is a former President and CEO of Children's National Hospital, and he has not yet been named to any board committee. The filing reports no financial results, so the change is a board composition update for shareholders.
Appointed as a director effective July 1, 2025; not yet named to any board committee.
Served as President and CEO of Children's National Hospital for 12 years, after more than 25 years there as a pediatric surgeon.
Receives standard non-employee director compensation and will enter the company's standard indemnification agreement.
Filing states no related-person transactions above $120,000 since the start of the last fiscal year, other than as described.
Pediatrix Medical Group reported first-quarter 2025 net income of $20.7 million, or $0.24 per diluted share, up from $4.0 million, or $0.05, a year earlier. Net revenue fell to $458.4 million from $495.1 million, mainly due to practice dispositions, and the company raised its full-year 2025 Adjusted EBITDA outlook to $220 million to $240 million from $215 million to $235 million.
Q1 2025 net income of $20.7 million ($0.24 per diluted share) vs. $4.0 million ($0.05) in Q1 2024
Q1 2025 net revenue of $458.4 million vs. $495.1 million, reflecting practice dispositions; same-unit net revenue grew 6.2 percent
Q1 2025 Adjusted EBITDA of $49.2 million vs. $37.2 million; Adjusted EPS of $0.33 vs. $0.20
Full-year 2025 Adjusted EBITDA outlook raised to $220 million to $240 million from $215 million to $235 million
Pediatrix subsidiary PMG Services amended its existing services agreement with Guidehouse Managed Services, extending the current Statement of Work #1 through June 30, 2025. The company also entered a new Statement of Work #2 under which Guidehouse will provide services starting July 1, 2025, with PMG Services paying fixed, variable and performance-based incentive fees. The filing does not disclose dollar amounts, so the financial size of the arrangement is unknown.
Agreements dated April 15, 2025, under a Master Services Agreement dated April 19, 2024
Statement of Work #1 term extended from April 19, 2025 through June 30, 2025
New Statement of Work #2 begins July 1, 2025, with fixed, variable and incentive payments
Pediatrix Medical Group reported fourth-quarter 2024 net income of $30.5 million, or $0.36 per diluted share, compared with a net loss of $124.3 million a year earlier, on net revenue of $502.4 million. For the full year, revenue rose to $2.01 billion, but the net loss widened to $99.1 million, and the company gave a preliminary 2025 Adjusted EBITDA range of $215 million to $235 million. Shareholders face mixed signals: a stronger quarter after portfolio exits, alongside a larger full-year loss that included $64.3 million in transformational and restructuring expenses.
Q4 2024 net revenue was $502.4 million, up from $496.4 million; net income was $30.5 million, or $0.36 per diluted share, versus a net loss of $124.3 million, or $1.50 per share, in Q4 2023.
Full-year 2024 net loss was $99.1 million, or $1.19 per share, compared with $60.4 million, or $0.73 per share, in 2023; full-year Adjusted EBITDA was $224.0 million versus $200.4 million.
Preliminary 2025 Adjusted EBITDA is expected to be in a range of $215 million to $235 million.
Total debt was $616 million at December 31, 2024, and cash and cash equivalents were $229.9 million.
Pediatrix Medical Group's board appointed Mark S. Ordan, a director and the company's Executive Chair, as chief executive officer effective January 12, 2025, succeeding Dr. James D. Swift. Dr. Swift's departure is treated as a termination without Cause, and Mr. Ordan's employment agreement sets a $1 million salary, a $2 million retention award and a 150% target bonus.
Mark S. Ordan appointed CEO effective January 12, 2025; Dr. James D. Swift steps down as CEO
Ordan's pay includes a $1 million salary, a $2 million one-time retention award and a target bonus of 150% of salary
Performance share award covers 640,000 shares, with vesting tied to stock price hurdles of 125%, 150% and 175% of the 20-day average close and a three-year anniversary
Ordan will remain Chair of the Board without additional board compensation
Pediatrix Medical Group said Executive Chair Mark S. Ordan will return as chief executive, effective immediately, succeeding James D. Swift, M.D. The company also said it currently believes it will reach the high end of its $205 million to $215 million 2024 adjusted EBITDA outlook and that the result may exceed that range, which would be an upward move from the prior guidance.
Mark S. Ordan appointed CEO effective immediately, succeeding James D. Swift, M.D., who will assist during the transition
Prior 2024 adjusted EBITDA outlook was $205 million to $215 million; company now expects the high end or possibly more
Fourth quarter and full year 2024 results to be announced February 20, 2025
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Pediatrix Medical filing is on SEC EDGAR ↗. 8-K briefs of other companies →